EMEA-001849-PIP02-15-M04

Table of contents

Key facts

Invented name
Bavencio
Active substance
avelumab
Therapeutic area
Oncology
Decision number
P/0546/2021
PIP number
EMEA-001849-PIP02-15-M04
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
  • Treatment of malignant neoplasms of lymphoid tissue
  • Treatment of malignant neoplasms of the central nervous system
Route(s) of administration
Intravenous use
Contact for public enquiries
Merck Healthcare KGaA

Email: service@merckgroup.com
Tel. +49 6151725200
 

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating